Nabi reports successful reduction in S. aureus bacteremias at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Toronto, Canada , September 19, 2000 -- Nabi (Nasdaq: NABI) announced preliminary results from the phase III clinical trial for StaphVAX™ (Staphylococcus aureus conjugate vaccine) at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Toronto, Canada. The data from the trial demonstrated a dramatic reduction in S. aureus bacteremias (blood stream infections) during the first ten months of the study. However, the decrease in bloodstream infections after one-year follow up, the primary endpoint for the study, did not achieve statistical significance. The study was performed by the Kaiser Permanente Vaccine Study Center based in Oakland, CA, and the preliminary results were presented by the principal investigators from that institution, Steven Black, M.D. and Henry Shinefield, M.D.

"We are excited by the data from this trial," said David J. Gury, Chairman, President and Chief Executive Officer of Nabi. "Based on the protection exhibited for StaphVAX treated patients during the first ten months of the trial, we strongly believe that a CPS-conjugated vaccine against S. aureus is feasible. Moreover, the demonstration that StaphVAX-induced antibodies can protect against bloodstream infections has very positive implications for the success of Nabi's entire Gram-positive program."

In reviewing the preliminary results from the trial, Dr. Black stated, "Through ten months, the study results found 57% fewer cases of Staph aureus disease in these immune compromised study participants who received the vaccine. Staph aureus is an increasing, lethal bacteria, which causes significant morbidity and mortality."

Dr. Shinefield affirmed, "These results are particularly important at a time of growing resistance of Staph aureus to antibiotics."

StaphVAX consists of capsular polysaccharides (CPS) from the two most common serotypes of S. aureus (Type 5 and Type 8), each conjugated to a carrier protein. The double-blinded, placebo-

Contact: Joan Kureczka
Kureczka/Martin Associates

Page: 1 2

Related biology news :

1. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
2. Scientists question reports of massive ant supercolonies in California and Europe
3. Survey reports fall in stem cell transplants for breast cancer
4. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
5. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine
6. By the year 2050, human population could add 2.6 billion people, reports Rockefeller scientist
7. Measles on the rise as vaccinations fall in the UK, Science study reports
8. WCS biologist George Schaller reports surprising increase in Tibets wildlife
9. Clinical study reports findings of combination therapy with DOXIL
10. Europes population has developed new tendency to shrink, Science study reports
11. U of A scientist finds Atlantic salmon escapes higher than government reports

Post Your Comments:

(Date:6/4/2019)... ... June 04, 2019 , ... ... for salient features of seizure risk signals, usually based on variations of amplitude, ... remains the only acceptable diagnostic methodology due to the complexity and variability of ...
(Date:6/1/2019)... ... 2019 , ... The University of Vermont Health Network Ventures ... Series B Financing Round. , “With the commitment from the UVM fund ... and business resources to bear as we advance our biopharmaceutical products to the ...
(Date:5/31/2019)... (PRWEB) , ... May 30, 2019 , ... ... Comprehend in a live webinar on Wednesday, June 19, 2019 ... clinical operations teams, medical review teams, data management teams and contract research organizations ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... , ... June 11, 2019 , ... ... Personalized Stem Cells Inc. (PSC) , has announced that their GMP facility ... Food and Drug Branch for manufacturing. This is an important milestone for ...
(Date:5/31/2019)... ... May 29, 2019 , ... For many years, the ... forms of cancer demand breakthrough therapies. Advances in immuno-oncology have led to the advent ... T cells with engineered T cell receptors known as “CARs”. The CAR enables the ...
(Date:5/31/2019)... ... May 30, 2019 , ... Object Pharma, Inc., ... strategic acquisition of Metabiologics, Inc., a globally recognized leader in the production and ... commercialization rights to a full spectrum of botulinum neurotoxins, as well as a ...
(Date:5/21/2019)... ... 21, 2019 , ... DuPont Nutrition & Biosciences (DuPont) and ... Brewing Conference dedicated to sharing brewing knowledge, strengthening relationships and discussing best practices ... through a partnership with “Ethiopia Invest”, will run through May 23, 2019, in ...
Breaking Biology Technology:
Cached News: